

developing a clinical pipeline of orally
administered, small molecule therapies
for chronic inflammatory and
autoimmune diseases.
Selective
Oral Drugs in
Immunology


small molecule programs, each of which has
unique features intended to directly address the
unmet needs of patients with serious chronic
inflammatory and autoimmune diseases.
Programs in
Clinical
Development


oral treatment options with comprehensive
therapeutic efficacy and outstanding
safety and tolerability for patients with
multiple sclerosis.


and well-tolerated orally available
treatment options to patients suffering
from celiac disease in order to improve
their lives by eliminating the debilitating
symptoms of the disease.
Convenient,
Oral Treatment
Options Available
to Patients
Press Releases & Events
Latest News.
Questions?
Get in touch.
Immunic, Inc. (Nasdaq: IMUX) Stock Quote: